Epstein Secrets

TW launch in 2019 but would see $2/share of upside should MNTA launch at-risk (assuming approval). Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is - 16% of sales, ^21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in

TW launch in 2019 but would see $2/share of upside should MNTA launch at-risk (assuming approval). Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in c

19 but would see $2/share of upside should MNTA launch at-risk (assuming approval). Links to Notes EFTA00665657 • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (front Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 an

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in